使用抗GD2ADC和EZH2抑制剂治疗骨肉瘤的一种新的治疗策略
Jing Shan1, Zicheng Lin2, Harunor Rashid3
1School of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia.
Biomarker research
|June 18, 2025
概括
结合一个抗-disialoganglioside (GD2) 抗体-药物联合体 (ADC) 与tazemetostat,一个增强剂的zeste同类物2 (EZH2) 抑制剂,通过增加GD2表达和增强ADC疗效,显著改善骨髓瘤治疗.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 骨髓瘤是一种常见的儿科骨癌,治疗选择有限,预后不佳.
- 滴立方化物 (GD2) 是抗体-药物联合体 (ADC) 的抗原,但其在骨髓瘤细胞上的低表达限制了ADC的有效性.
- 增强性凝血同源2 (EZH2) 抑制剂可以调节基因表达,可能对癌症治疗的标抗原进行上调.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K